Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

Beating balls of heart cells created from skin biopsies of children with a rare inherited disorder called Timothy syndrome replicate the abnormal heart rhythms that characterize the disease. The cells provide a new way to search for drugs to treat the disease, which is linked to autism and serious—sometimes fatal—heart problems.

Researchers have already identified one compound that normalizes heart rhythms in cells growing in a dish. In addition to benefiting research into Timothy syndrome, the cells might be useful for detecting drug compounds that trigger or exacerbate abnormal heart rhythms, one of the most common reasons for drugs to be pulled off the market.

The findings, published Thursday in Nature, are part of a growing trend to create stem cells from patients with specific diseases, such as heart disease, neurodegenerative disorders, and developmental disorders, and use these cells to recreate the disease of interest in a dish. Although scientists have previously created cells from people with Down syndrome, ALS, diabetes, and inherited forms of heart disease related to Timothy syndrome, this study is among the first to use the cells to screen compounds intended to reverse the defects seen in the cells.

“Even though we know the gene mutation for many of these diseases, people haven’t always connected the dots in terms of how the mutation leads to the arrhythmia [abnormal heart rhythm],” says Michael Laflamme, a physician-scientist in the Center for Cardiovascular Biology at the University of Washington, who was not involved in the study. “That’s where these cells come in.”

Ricardo Dolmetsch, a neurobiologist at Stanford, and collaborators collected skin cells from two young patients with Timothy syndrome and returned them to a stem-cell state with a technique called induced pluripotent stem (iPS) cell reprogramming. Like embryonic stem cells, iPS cells can be differentiated into any type of tissue, making them a potential source of tissue for drug screening and perhaps tissue-replacement therapies.

The researchers treated the stem cells with chemicals to prod them to develop into heart tissue. After growing for about a month in a dish, the cells developed into beating masses of tissue made of each of the three cell types in the heart; atrial, ventricular, and nodal cells. When the cells are made from people with normal hearts, “they beat beautifully at 60 beats per minute, just like human hearts,” says Dolmetsch. However, when derived from stem cells created from patients with cardiac disease, they beat more slowly and missed certain beats, he says. “Something is clearly wrong with them.”

0 comments about this story. Start the discussion »

Credit: Ricardo Dolmetsch

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me